PAUL B MCCRAY, MD
Medical Practice at Hawkins Dr, Iowa City, IA

2013006, Mar 14, 2013

Sep 13, 2011

13/231324

Paul McCray - Iowa City IA, US
Patrick Sinn - Iowa City IA, US
Gary Blissard - Ithaca NY, US

UNIVERSITY OF IOWA RESEARCH FOUNDATION - Iowa City IA
BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH - Ithaca NY

C12N 7/00

4352351

A method of co-expressing a portion of the VSV G protein gene or a truncated “stem” portion with GP64 and a retrovirus increases the titer of retroviral vectors. A truncated VSV G protein, preferably comprised of a small segment from the C-terminal portion of the ectodomain plus the transmembrane (TM) and cytoplasmic tail (CTD) domains of VSV G, co-expressed with retroviral vectors, enhances the production titers of the retroviral vectors. A preferred embodiment uses a VSV G construct that includes an N-terminal c-Myc epitope plus 42 amino acids from the C-terminal portion of the ectodomain, 20 amino acids from the predicted TM domain, and 29 amino acids from the predicted CTD of the VSV G protein.

7608449, Oct 27, 2009

May 13, 2004

10/845253

Paul McCray - Iowa City IA, US
Hung Fan - Laguna Beach CA, US
Patrick Sinn - Iowa City IA, US

The Regents of the University of California - Oakland CA
The University of Iowa Research Foundation - Iowa City IA

C12N 15/00, C12N 7/00

4353201, 4352351

The present invention concerns the methods and compositions related to pseudotyped viral vectors. Embodiments of the invention include pseudotyping expression cassettes that include nucleic acid elements for enhancing the titer of pseudotyped viral particles. Embodiments of the invention include novel methods and compositions related to making high titer pseudotyped retroviral vector compositions. A heterologous envelope glycoprotein is typically incorporated into the virus during the budding or virus production process. Certain embodiments of the invention include pseudotyped retroviral vectors comprising a heterologous envelope glycoprotein derived from a Jaagsiekte sheep retrovirus (JSRV env). Pseudotyped viruses or viral particles may have a modified host range that is influenced by the properties of the heterologous envelope glycoprotein. Thus, embodiments of the invention include improved methods and compositions related to pseudotyped viruses suitable for ex vivo and in vivo methods including gene transfer and other therapeutic and experimental methods.

2014008, Mar 20, 2014

Sep 18, 2013

14/030731

Paul B. McCray - Iowa City IA, US
Beverly L. Davidson - Iowa City IA, US
Abhay Divekar - Iowa City IA, US

University of Iowa Research Foundation - Iowa City IA

A61K 48/00

604508

The present invention relates to a safe and effective way to deliver and express therapeutic compositions (e.g., transgenes) to the pancreas and lungs of a mammal.

2005019, Sep 1, 2005

Dec 3, 2004

11/003126

Paul McCray - Iowa City IA, US
Jerry Weiss - Coralville IA, US
Hong Jia - Iowa City IA, US
Brian Schutte - Iowa City IA, US
Jennifer Bartlett - Coralville IA, US

A61K038/17, A61K031/7048, A61K031/704, A61K031/65, A61K031/496, A61K031/4745

514012000, 514008000, 514035000, 514154000, 514192000, 514252130, 514291000, 514029000, 514037000, 514039000

The present invention concerns compositions and methods related to the use of peptides and polypeptides corresponding to all or part of the SPLUNC1 and LPLUNC1 proteins. Particular aspects of the invnetion include the use of SPLUNC1 and LPLUNC1 peptides and polypeptides as antimicrobials, anti-inflammatory, and immune modulatory agents.

2005012, Jun 9, 2005

Nov 19, 2004

10/993319

Paul McCray - Iowa City IA, US
Beverly Davidson - North Liberty IA, US
Colleen Stein - Iowa City IA, US

A61K048/00, C12N007/00, C07K014/005, C12N015/86

424093200, 435456000, 435235100, 530395000

The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.

2005011, May 26, 2005

Mar 26, 2004

10/811353

Paul McCray - Iowa City IA, US
David Sanders - West Lafayette IN, US
Scott Jeffers - Aurora CO, US
Beverly Davidson - North Liberty IA, US
Patrick Sinn - Iowa City IA, US

Purdue Research Foundation - West Lafayette IN
University of Iowa Research Foundation - Iowa City IA

A61K048/00, A61K038/16

424093200, 514044000, 514008000

The invention provides a method to introduce a selected nucleic acid sequence into an airway epithelial cell that involves contacting the airway epithelial cell with a pseudotyped retrovirus that includes a glycoprotein in which a portion of an O-glycosylation region within the glycoprotein has been deleted and a retroviral capsid that includes the selected nucleic acid sequence. The invention also provides a method to reduce or eliminate the symptoms of cystic fibrosis in a mammal that involves contacting an airway epithelial cell of the mammal with a pseudotyped retrovirus that includes a glycoprotein in which a portion of an O-glycosylation region within the glycoprotein has been deleted and a retroviral capsid that includes a nucleic acid sequence that encodes a cystic fibrosis transmembrane regulator protein.

2011008, Apr 14, 2011

Oct 15, 2010

12/905824

Paul McCray - Iowa City IA, US
Morgan Maeder - Brookline MA, US
Jae Keith Joung - Winchester MA, US

A61K 38/46, C12N 9/16, C12N 15/63, C12N 15/00, A61P 3/00, C07K 7/06

424 946, 435196, 4353201, 435440, 530329

The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

2005011, May 26, 2005

Nov 20, 2003

10/718262

Paul McCray - Iowa City IA, US
Beverly Davidson - North Liberty IA, US

A61K048/00, C12N005/06, C12N015/867

424093200, 435456000, 435235100, 435325000

The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy.

7687475, Mar 30, 2010

Oct 16, 2007

11/974835

Paul B. McCray - Iowa City IA, US
Beverly L. Davidson - North Liberty IA, US
Anthony J. Fischer - Iowa City IA, US
Hong P. Jia - Iowa City IA, US
Maureen D. Donovan - Swisher IA, US
Patrick L. Sinn - Iowa City IA, US
Mark Aaron Behlke - Coralville IA, US

University of Iowa Research Foundation - Iowa City IA

A61K 31/70, C07H 21/04, C12N 15/00

514 44, 536 245, 4353201

The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules.